ArticleGut2021
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.
Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 133 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Blood Biomarkers to Predict Gastric Cancer Risk
Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Who cites it
133 citing papers in PubMed, 3 syntheses or guidelines pooled it, 196 citations in OpenAlex.
- Economic Evaluation of Gastric Cancer Screening Strategies: A Systematic Review.Journal of gastrointestinal cancer · 2025Pooled it
- Health Economic Evidence and Modeling Challenges for Liquid Biopsy Assays in Cancer Management: A Systematic Literature Review.PharmacoEconomics · 2023Pooled it
- Gastric cancer detection by non-blood-based liquid biopsies: A systematic review looking into the last decade of research.United European gastroenterology journal · 2023Pooled it
- Liquid biopsy for early detection of pancreatic ductal adenocarcinoma.Nature medicine · 2026Article
- A Dual-Mode In Situ EV-miRNA Profiling Platform for Machine-Learning-Assisted Gastric Cancer Liquid Biopsy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrating serological markers of Helicobacter pylori and pepsinogen to improve detection of gastric precancerous conditions.BMC gastroenterology · 2026Observational
- Circulating cell-free mtDNA fragmentomics for early detection of gastric cancer and precancerous lesions.Cell reports. Medicine · 2026Article
- Extracellular vesicle and particle biomarkers in cancer: a machine learning blueprint for liquid biopsy.Journal of nanobiotechnology · 2026Review
- Optimal upper gastrointestinal surveillance strategies for gastric, small bowel and pancreatic cancer detection in Lynch syndrome.Familial cancer · 2026Review
- Integrated serum proteomics and metabolomics reveal an INR-associated multi-omics signature in hepatocellular carcinoma.Clinical proteomics · 2026Article
- Development and validation of a novel blood-based biomarker for gastric cancer triage in chronic dyspepsia.NPJ digital medicine · 2026Article
- FNDC1 is closely related to poor prognosis and immune cell infiltration in gastric cancer.Scientific reports · 2026Article
- Development and Validation of a Urinary Exosomal miRNA Diagnostic Panel for Early Detection of Esophageal Cancer.Cancer science · 2026Article
- Prevention of Gastric Cancer.Medicina (Kaunas, Lithuania) · 2026Review
- Identification of potential hub biomarkers for gastric high-grade intraepithelial neoplasia early diagnosis: evidence from gene expression profiles and pathological characters.Translational cancer research · 2026Article
- A selective enrichment and specific probe terminal mediated strategy for highly sensitive detection of microRNAs.Nature communications · 2026Article
- Enzymatic colorimetric encoding-based digital medicine for pancreatic cancer diagnosis.Nature communications · 2026Article
- Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies.Clinical and translational medicine · 2026Review
- MicroRNA-VEGF axis in gastric cancer: a novel therapeutic frontier.Discover oncology · 2026Review
- Novel Liquid Biopsy in Gastrointestinal Cancers.Journal of gastroenterology and hepatology · 2026Review
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAn unmet need exists for a non-invasive biomarker assay to aid gastric cancer diagnosis. We aimed to develop a serum microRNA (miRNA) panel for identifying patients with all stages of gastric cancer from a high-risk population.
designWe conducted a three-phase, multicentre study comprising 5248 subjects from Singapore and Korea. Biomarker discovery and verification phases were done through comprehensive serum miRNA profiling and multivariant analysis of 578 miRNA candidates in retrospective cohorts of 682 subjects. A clinical assay was developed and validated in a prospective cohort of 4566 symptomatic subjects who underwent endoscopy. Assay performance was confirmed with histological diagnosis and compared with
resultsWe developed a clinical assay for detection of gastric cancer based on a 12-miRNA biomarker panel. The 12-miRNA panel had area under the curve (AUC)=0.93 (95% CI 0.90 to 0.95) and AUC=0.92 (95% CI 0.88 to 0.96) in the discovery and verification cohorts, respectively. In the prospective study, overall sensitivity was 87.0% (95% CI 79.4% to 92.5%) at specificity of 68.4% (95% CI 67.0% to 69.8%). AUC was 0.848 (95% CI 0.81 to 0.88), higher than HP serology (0.635), PG 1/2 ratio (0.641), PG index (0.576), ABC method (0.647), CEA (0.576) and CA19-9 (0.595). The number needed to screen is 489 annually. It is cost-effective for mass screening relative to current practice (incremental cost-effectiveness ratio=US$44 531/quality-of-life year).
conclusionWe developed and validated a serum 12-miRNA biomarker assay, which may be a cost-effective risk assessment for gastric cancer. TRIAL REGISTRATION NUMBER: This study is registered with ClinicalTrials.gov (Registration number: NCT04329299).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.